ClinicalTrials.gg
RecruitingNCT05675410Updated Nov 12, 2026

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

A Phase 3 interventional study of Biospecimen Collection and Bleomycin Sulfate in Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8, sponsored by National Cancer Institute (NCI). Recruiting at 419 sites in 3 countries. Open to participants aged 5 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by National Cancer Institute (NCI) · Phase 3, Interventional, and Treatment

How we know · 27 judgments

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.
Updated Nov 5, 2026Site recruiting status changed5 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,875
Allocation
Randomized
Ages
5 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.

Planned enrollment
Largest of 80
1,875 · median 52
Started
2023
with 1 other
Phase 3
8 of 80
2 open now
Primary completion
2031-04
later than 27 of 27 live
Registered
72nd of 80
by date
Lead sponsor
6 of 80
National Cancer Institute (NCI)

Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one has the largest planned enrollment, is one of 2 that started in 2023, is one of 8 in phase 3, reaches primary completion later than 27 of the 27 other live ones, and was the 72nd registered.

Hodgkin Disease

1,384 studies on the registry are indexed under Hodgkin Disease; 160 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Hodgkin Disease studies recruiting now, 70 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 5 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing Brentuximab Vedotin in Hodgkin Disease, or all of them as a file.
02

Study summary

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine, and procarbazine hydrochloride work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Adding immunotherapy to the standard treatment of chemotherapy with or without radiation may increase survival and/or fewer short-term or long-term side effects in patients with classical Hodgkin lymphoma compared to the standard treatment alone.

Read the detailed description

PRIMARY OBJECTIVES:

I. To compare the progression-free survival (PFS) of a standard chemotherapy approach versus an immunotherapy (IO) approach (brentuximab vedotin and nivolumab) in patients with newly diagnosed early stage classic Hodgkin lymphoma (cHL) who have a rapid early response (RER) as determined by position emission tomography post cycle 2 (PET2) after 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy.

II. To compare the PFS of a standard chemotherapy approach versus an IO therapy approach (brentuximab vedotin and nivolumab) plus involved site radiation therapy (ISRT) in patients with newly diagnosed early stage cHL who have a slow early response (SER) as determined by PET2 after 2 cycles of ABVD chemotherapy.

SECONDARY OBJECTIVES:

I. To demonstrate non-inferiority of overall survival (OS) at 12 years of IO therapy versus standard therapy in early stage cHL patients who have a RER as determined by PET2 after 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy.

II. To evaluate the overall survival (OS) at 12 years of IO therapy versus standard therapy in early stage cHL patients who have a SER as determined by PET2 after 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy.

III. To demonstrate non-inferiority of overall survival (OS) at 12 years of IO therapy versus standard therapy in early stage cHL patients.

IV. To evaluate in patients with newly diagnosed early stage cHL the PFS of a standard chemotherapy approach versus an IO therapy approach (brentuximab vedotin and nivolumab) in the overall cohort, in the favorable risk cohort, and in the unfavorable risk cohort.

V. To evaluate the event-free survival (EFS) at 12 years of patients undergoing standard chemotherapy versus an IO therapy approach (brentuximab vedotin and nivolumab).

VI. To compare the physician-reported treatment-related adverse event (AE) rates between a standard chemotherapy approach and an IO therapy approach (brentuximab vedotin and nivolumab) in patients with newly diagnosed early stage cHL.

VII. To compare patient-reported adverse events using pediatric and adult versions of Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), stratified by age groups, therapeutic arms, and receipt of radiation therapy (RT) over time.

VIII. To evaluate changes in patient-reported fatigue, cognitive functioning, and health-related quality of life (HRQoL), e.g., emotional, physical, and role functioning, by treatment arm, using validated adult and pediatric measurement systems.

IX. To evaluate self-reported late morbidities (e.g., cardiovascular, pulmonary and endocrine) over time for children, adolescents and adults undergoing standard chemotherapy versus an IO therapy approach (brentuximab vedotin and nivolumab) with and without RT using measures from the St. Jude Lifetime Cohort Study (SJLIFE).

X. To evaluate fludeoxyglucose F-18 (FDG)-position emission tomography (PET) measurements of metabolic tumor burden (MTV and total lesion glycolysis [TLG]) at PET at baseline (PET1) as a predictive marker of PFS.

XI. To evaluate the associations between race/ethnicity and key outcomes including early response to therapy, PFS and OS.

EXPLORATORY OBJECTIVES:

I. To evaluate the PFS of a standard chemotherapy approach versus an IO therapy approach (brentuximab vedotin and nivolumab) in patients with newly diagnosed early stage cHL across different age groups (ages 5-11 years, 12-21 years, 22-39 years, 40-60 years).

II. To bank specimens for future correlative studies. III. To assess concordance and discordance of rapid central review and local institutional review of FDG PET 5-point score (5-PS; previously referred to as Deauville score) at baseline PET1, interim PET2 and end of systemic therapy PET-end of systemic therapy (EST) SER.

IV. To assess the association between PFS and the quantitative FDG-PET/computed tomography (CT) parameters (PET MTV, TLG, delta-standardized uptake value [SUV] and PET SUV-based quantitative surrogates [qPET] of visual qualitative 5-PS) on measurements by automated measurements using convolutional neural networks (CNNs) through artificial-intelligence (AI) machine learning in the entire population.

V. To assess the agreement between quantitative FDG-PET/CT parameters obtained using AI and those based on measurements by a trained imaging physician.

VI. To compare patient-reported adverse events (via pediatric [Ped]-PRO-CTCAE and PRO-CTCAE) to provider adverse event reporting.

VII. To evaluate the association between self-reported race/ethnicity and social determinants of health.

VIII. To evaluate the associations between race/ethnicity and post-progression/post-relapse overall survival.

IX. To evaluate the completion rates of PRO and health-related quality of life (HRQoL) contact forms at 1 year off treatment for the first 450 eligible patients.

X. To collect contact information from participants for future re-contact.

OUTLINE: Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride intravenously [IV] over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or magnetic resonance imaging (MRI) and are identified as RER or SER.

Patients with a favorable risk status and RER are randomized to Arm A or Arm B. Patients with a favorable risk status and SER are randomized to Arm C or Arm D. Patients with an unfavorable risk status and RER are randomized to Arm E or Arm F. Patients with an unfavorable risk status and SER are randomized to Arm G or Arm H.

ARM A (RER, FAVORABLE): Patients receive ABVD IV for an additional 2 cycles on study. Each cycle lasts 28 days and ABVD is administered on days 1 and 15 of each cycle in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

ARM B (RER, FAVORABLE): Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes once during each treatment cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

ARM C (SER, FAVORABLE): Patients receive either the eBEACOPP regimen (doxorubicin hydrochloride IV over 3-15 minutes on day 1, cyclophosphamide IV over 30-60 minutes on day 1, etoposide or etoposide phosphate IV over 2-4 hours on days 1-3, prednisone or prednisolone orally [PO] twice daily [BID] on days 1-14, procarbazine hydrochloride PO on days 1-7, bleomycin sulfate IV over at least 10 minutes on day 8, and vincristine sulfate IV on day 8 of each cycle) or the eBPDac regimen (doxorubicin hydrochloride IV 3-15 minutes on day 1, cyclophosphamide IV 30-60 minutes on day 1, etoposide or etoposide phosphate IV over 2-4 hours on days 1-3, prednisone or prednisolone PO BID on days 1-14, dacarbazine IV over 15-60 minutes on days 2 \& 3, bleomycin sulfate IV over at least 10 minutes on day 4, 5, 6, 7, or 8, vincristine sulfate IV on day 4, 5, 6, 7, or 8 of each cycle). Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Subsequently, patients undergo ISRT. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

ARM D (SER, FAVORABLE): Patients receive brentuximab vedotin IV and nivolumab IV as in arm B followed by ISRT. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

ARM E (RER, UNFAVORABLE): Patients receive AVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, vinblastine IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

ARM F (RER, UNFAVORABLE): Patients receive treatment as in arm B. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

ARM G (SER, UNFAVORABLE): Patients receive treatment and imaging, and may undergo blood sample collection as in arm C.

ARM H (SER, UNFAVORABLE): Patients receive treatment and imaging, and may undergo blood sample collection as in arm D.

After completion of study treatment, patients are followed up every 3 months for the first year, then every 6 months for the second and third year, then annually until 12 years from date of registration.

03

Conditions studied

  • Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Browse trials for

04

Who can participate

Ages eligible
5 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be 5 to 60 years of age at the time of enrollment
  • Patients with newly diagnosed untreated confirmed classic Hodgkin lymphoma (cHL) (nodular sclerosis, mixed cellularity, lymphocyte-rich, or lymphocyte-depleted, or not otherwise specified [NOS]) with stage I or II disease
  • Patients must have bidimensionally (at least one lesion with longest diameter >= 1.5 cm)
  • Patients must have a whole body or limited whole body PET scan performed within 42 days prior to enrollment. PET-CT is strongly preferred. PET-MRI allowed if intravenous contrast enhanced CT is also obtained
  • Pediatric patients (age 5-17 years) with known or suspected mediastinal disease must have an upright posteroanterior (PA) chest X-ray (CXR) for assessment of bulky mediastinal disease.

    • Note: Pediatric patients who have received both a CT chest and upright PA CXR may meet the definition of bulk through either modality.
  • Patients >= 18 years must have a performance status corresponding to Zubrod scores of 0, 1 or 2
  • Patients =\< 17 years of age must have a Lansky performance score of >= 50
  • Pediatric patients (age 5-17 years): A serum creatinine based on age/sex as follows (within 28 days prior to enrollment):

    • 2 to \< 6 years (age): 0.8 mg/dL (male), 0.8 mg/dL (female)
    • 6 to \< 10 years (age): 1 mg/dL (male), 1 mg/dL (female)
    • 10 to \< 13 years (age): 1.2 mg/dL (male), 1.2 mg/dL (female)
    • 13 to \< 16 years (age): 1.5 mg/dL (male), 1.4 mg/dL (female)
    • >= 16 years (age): 1.7 mg/dL (male), 1.4 mg/dL (female) OR a 24 hour urine >= 50 mL/min/1.73 m\^2 (within 28 days prior to enrollment) OR a (GFR) >= 50 mL/min/1.73 m\^2 (within 28 days prior to enrollment). GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard)
    • Note: Estimated GFR (eGFR) from serum or plasma creatinine, cystatin C or other estimates are not acceptable for determining eligibility
  • For adult patients (age 18 years or older) (within 28 days prior to enrollment): Creatinine clearance >= 30 mL/min, as estimated by the Cockcroft and Gault formula or a 24-hour urine collection. The creatinine value used in the calculation must have been obtained within 28 days prior to registration. Estimated creatinine clearance is based on actual body weight
  • Total =\< 2 x (ULN) (within 28 days prior to enrollment)

    • Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome
  • (AST) =\< 3 x ULN (within 28 days prior to enrollment)

    • Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome
  • Alanine aminotransferase (ALT) =\< 3 x ULN (within 28 days prior to enrollment)

    • Unless due to Gilbert's disease, lymphomatous involvement of liver or vanishing bile duct syndrome
  • Shortening fraction of >= 27% by echocardiogram (ECHO), multigated acquisition scan (), or functional cardiac imaging scan (within 28 days prior to enrollment) or ejection fraction of >= 50% by radionuclide angiogram, ECHO, MUGA, or cardiac imaging scan (within 28 days prior to enrollment)
  • Diffusion capacity of the lung for carbon monoxide (DLCO) >= 50% of predicted value as corrected for by pulmonary function test (PFT) (within 28 days prior to enrollment). If unable to obtain PFTs, the criterion is: a pulse oximetry reading of > 92% on room air
  • Known (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • For patients with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

Exclusion criteria

Exclusion Criteria:

  • Patients with nodular lymphocyte predominant Hodgkin lymphoma
  • Patients with a history of active interstitial pneumonitis or interstitial lung disease
  • Patients with a diagnosis of inherited or acquired immunodeficiency that is poorly controlled or requiring active medications, such as primary immunodeficiency syndromes or organ transplant recipients
  • Patients with any known uncontrolled intercurrent illness that would jeopardize the patient's safety such as infection, conditions, cardiac arrhythmias, angina pectoris, and gastrointestinal disorders affecting swallowing and/or absorption of pills
  • Patients with a condition requiring systemic treatment with either (defined as equivalent to > 10 mg daily predniSONE for patients >= 18 years or > 0.5 mg/kg [up to 10 mg/day] for patients \< 18 years) or other medications within 14 days prior to enrollment

    • Note: Replacement therapy such as thyroxine, insulin, or physiologic corticosteroid for adrenal or pituitary insufficiency is not considered a form of systemic treatment. Inhaled or topical steroids, and adrenal replacement doses (=\< 10 mg daily for patients >= 18 years or =\< 0.5 mg/kg [up to 10 mg/day] predniSONE equivalents) are permitted in the absence of active autoimmune disease
    • Note: Steroid use for the control of Hodgkin lymphoma symptoms is allowable, but must be discontinued by cycle 1, day 1
    • Short term use of corticosteroids for premedication or treatment of an allergy or is considered an acceptable use of corticosteroids.
  • Patients with peripheral neuropathy > grade 1 at the time of enrollment or patients with known Charcot-Marie-Tooth syndrome
  • Patients with a prior or concurrent whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the regimen
  • Administration of prior chemotherapy, radiation, or antibody-based treatment for cHL
  • Prior solid organ transplant
  • Prior stem cell transplantation
  • within 30 days prior to planned day 1 of protocol therapy (e.g., measles, mumps, rubella, varicella, yellow fever, rabies, bacillus Calmette Guerin [BCG], oral polio vaccine, and oral typhoid). Administration of messenger ribonucleic acid (mRNA) vaccines are permitted
  • Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test within 28 days prior to enrollment is required for female patients of
  • Lactating females who plan to breastfeed their infants starting with the first dose of study therapy and for at least 6 months after the last treatment
  • Sexually active patients of who have not agreed to use a highly effective method for the duration of their study drug therapy. Following therapy, patients will be advised to use contraception as per institutional practice or as listed below for investigational agents, whichever is longer

    • Men and women of childbearing potential (WOCBP) must use effective contraception during the study and for 2 months for WOCBP and 4 months for men, after last dose of brentuximab vedotin
    • WOCBP must continue contraception for a period of at least 5 months after the last dose of nivolumab
  • All patients and/or their parents or legal guardians must sign a written
  • All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
1,875 participants (estimated)

Study arms

  • Active comparator
    Arm A (ABVD)

    Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive ABVD IV for an additional 2 cycles on study. Each cycle lasts 28 days and ABVD is administered on days 1 and 15 of each cycle in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

    Procedure: Biospecimen Collection · Biological: Bleomycin Sulfate · Procedure: Computed Tomography · Drug: Dacarbazine · Drug: Doxorubicin Hydrochloride · Other: Fludeoxyglucose F-18 · Procedure: Magnetic Resonance Imaging · Procedure: Positron Emission Tomography · Other: Questionnaire Administration · Drug: Vinblastine Sulfate

  • Experimental
    Arm B (ABVD, brentuximab vedotin, nivolumab)

    Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes once during each treatment cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

    Procedure: Biospecimen Collection · Biological: Bleomycin Sulfate · Drug: Brentuximab Vedotin · Procedure: Computed Tomography · Drug: Dacarbazine · Drug: Doxorubicin Hydrochloride · Other: Fludeoxyglucose F-18 · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Procedure: Positron Emission Tomography · Other: Questionnaire Administration · Drug: Vinblastine Sulfate

  • Experimental
    Arm C (ABVD, eBEACOPP or eBPDac, ISRT)

    See Detailed Description.

    Procedure: Biospecimen Collection · Biological: Bleomycin Sulfate · Procedure: Computed Tomography · Drug: Cyclophosphamide · Drug: Dacarbazine · Drug: Doxorubicin Hydrochloride · Drug: Etoposide · Drug: Etoposide Phosphate · Other: Fludeoxyglucose F-18 · Radiation: Involved-site Radiation Therapy · Procedure: Magnetic Resonance Imaging · Procedure: Positron Emission Tomography · Drug: Prednisolone · Drug: Prednisone · Drug: Procarbazine Hydrochloride · Other: Questionnaire Administration · Drug: Vinblastine Sulfate · Drug: Vincristine Sulfate

  • Experimental
    Arm D (ABVD, brentuximab vedotin, nivolumab, ISRT)

    Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive brentuximab vedotin IV and nivolumab IV as in arm B followed by ISRT. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

    Procedure: Biospecimen Collection · Biological: Bleomycin Sulfate · Drug: Brentuximab Vedotin · Procedure: Computed Tomography · Drug: Dacarbazine · Drug: Doxorubicin Hydrochloride · Other: Fludeoxyglucose F-18 · Radiation: Involved-site Radiation Therapy · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Procedure: Positron Emission Tomography · Other: Questionnaire Administration · Drug: Vinblastine Sulfate

  • Experimental
    Arm E (ABVD, AVD)

    Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive AVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, vinblastine IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

    Procedure: Biospecimen Collection · Biological: Bleomycin Sulfate · Procedure: Computed Tomography · Drug: Dacarbazine · Drug: Doxorubicin Hydrochloride · Other: Fludeoxyglucose F-18 · Procedure: Magnetic Resonance Imaging · Procedure: Positron Emission Tomography · Other: Questionnaire Administration · Drug: Vinblastine Sulfate

  • Experimental
    Arm F (ABVD, brentuximab vedotin, nivolumab)

    Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive treatment as in arm B. Patients also undergo FDG-PET, PET, PET-CT, PET-MRI, CT, and/or MRI throughout the trial. Patients may also undergo blood sample collection on trial.

    Procedure: Biospecimen Collection · Biological: Bleomycin Sulfate · Drug: Brentuximab Vedotin · Procedure: Computed Tomography · Drug: Dacarbazine · Drug: Doxorubicin Hydrochloride · Other: Fludeoxyglucose F-18 · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Procedure: Positron Emission Tomography · Other: Questionnaire Administration · Drug: Vinblastine Sulfate

  • Experimental
    Arm G (ABVD, eBEACOPP or eBPDac, ISRT)

    Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive treatment and imaging, and may undergo blood sample collection as in arm C.

    Procedure: Biospecimen Collection · Biological: Bleomycin Sulfate · Procedure: Computed Tomography · Drug: Cyclophosphamide · Drug: Dacarbazine · Drug: Doxorubicin Hydrochloride · Drug: Etoposide · Drug: Etoposide Phosphate · Other: Fludeoxyglucose F-18 · Radiation: Involved-site Radiation Therapy · Procedure: Magnetic Resonance Imaging · Procedure: Positron Emission Tomography · Drug: Prednisolone · Drug: Prednisone · Drug: Procarbazine Hydrochloride · Other: Questionnaire Administration · Drug: Vinblastine Sulfate · Drug: Vincristine Sulfate

  • Experimental
    Arm H (ABVD, brentuximab vedotin, nivolumab, ISRT)

    Patients are stratified by risk status (favorable versus unfavorable) and then all patients receive the ABVD regimen (doxorubicin hydrochloride IV over 3-15 minutes, bleomycin sulfate IV over at least 10 minutes, vinblastine sulfate IV, and dacarbazine IV over 15-60 minutes) on days 1 and 15 of each treatment cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo FDG-PET/CT or MRI and are identified as RER or SER. Patients then receive treatment and imaging, and may undergo blood sample collection as in arm D.

    Procedure: Biospecimen Collection · Biological: Bleomycin Sulfate · Drug: Brentuximab Vedotin · Procedure: Computed Tomography · Drug: Dacarbazine · Drug: Doxorubicin Hydrochloride · Other: Fludeoxyglucose F-18 · Radiation: Involved-site Radiation Therapy · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Procedure: Positron Emission Tomography · Other: Questionnaire Administration · Drug: Vinblastine Sulfate

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • BiologicalBleomycinStudies of BleomycinBleomycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: Blanoxan, BleMomycine, Blenoxane, Bleo-cell, Bleo-S, Bleocin, Bleolem, Bleomycin Sulfas, Bleomycin Sulphate, Bleomycini Sulfas, Blexane, Oil Bleo

  • Given IV

    Also known as: ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN 35, SGN-35, SGN35

  • ProcedureComputed Tomography

    Undergo CT and/or PET-CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • Given IV

    Also known as: (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Frindovyx, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719

  • Given IV

    Also known as: 4-(Dimethyltriazeno)imidazole-5-carboxamide, 5-(Dimethyltriazeno)imidazole-4-carboxamide, Asercit, Biocarbazine, Dacarbazina, Dacarbazina Almirall, Dacarbazine - DTIC, Dacatic, Dakarbazin, Deticene, Detimedac, DIC, Dimethyl (triazeno) imidazolecarboxamide, Dimethyl Triazeno Imidazol Carboxamide, Dimethyl Triazeno Imidazole Carboxamide, dimethyl-triazeno-imidazole carboxamide, Dimethyl-triazeno-imidazole-carboximide, DTIC, DTIC-Dome, Fauldetic, Imidazole Carboxamide, Imidazole Carboxamide Dimethyltriazeno, WR-139007

  • DrugDoxorubicinStudies of DoxorubicinDoxorubicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex

  • Given IV

    Also known as: Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213

  • Given IV

    Also known as: Etopophos

  • OtherFludeoxyglucose F-18

    Undergo FDG-PET

    Also known as: 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18

  • RadiationInvolved-site Radiation Therapy

    Undergo ISRT

    Also known as: ISRT

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI and/or PET-MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • BiologicalNivolumab

    Given IV

    Also known as: ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo

  • ProcedurePositron Emission Tomography

    Undergo FDG-PET, PET, PET-CT, and/or PET-MRI

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

  • Given PO

    Also known as: (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, .delta.1-Hydrocortisone, Adnisolone, Aprednislon, Capsoid, Cortalone, Cortisolone, Dacortin H, Decaprednil, Decortin H, Delta(1)Hydrocortisone, Delta- Cortef, Delta-Cortef, Delta-Diona, Delta-F, Delta-Phoricol, Delta1-dehydro-hydrocortisone, Deltacortril, Deltahydrocortisone, Deltasolone, Deltidrosol, Dhasolone, Di-Adreson-F, Dontisolon D, Estilsona, Fisopred, Frisolona, Gupisone, Hostacortin H, Hydeltra, Hydeltrasol, Klismacort, Kuhlprednon, Lenisolone, Lepi-Cortinolo, Linola-H N, Linola-H-Fett N, Longiprednil, Metacortandralone, Meti Derm, Meticortelone, Opredsone, Panafcortelone, Precortisyl, Pred-Clysma, Predeltilone, Predni-Coelin, Predni-Helvacort, Prednicortelone, Prednisolonum, Prelone, Prenilone, Sterane

  • Given PO

    Also known as: .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone

  • DrugProcarbazineStudies of ProcarbazineProcarbazine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given PO

    Also known as: Benzamide, N-(1-methylethyl)-4-[(2-methylhydrazino) methyl]-, monohydrochloride (9CI), Ibenzmethyzine hydrochloride, Matulane, MIH hydrochloride, Natulan, Natulanar, Natunalar, NCI C01810, NCI-C01810, NCIC01810, p-(N'-methylhydrazinomethyl)-N-isopropylbenzamide hydrochloride, p-Toluamide, N-isopropyl-.alpha.-(2-methylhydrazino)-, monohydrochloride (8CI), PCB, PCB Hydrochloride, PCZ, Ro 4 6467/1, Ro 4-6467/1

  • OtherQuestionnaire Administration

    Ancillary studies

  • DrugVinblastineStudies of VinblastineVinblastine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: 29060 LE, 29060-LE, Exal, Velban, Velbe, Velsar, VINCALEUKOBLASTINE

  • DrugVincristineStudies of VincristineVincristine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) in rapid early responder (RER) patients

    Will compare the PFS of RER patients randomized to immunotherapy (IO) therapy (brentuximab vedotin-nivolumab) against those randomized to standard therapy. PFS curves will be estimated separately by arm using Kaplan Meier methodology, and the test will be a 1-sided log-rank test between the (pooled) IO and standard arms, stratified according to the stratification factors at randomization and including all eligible and evaluable randomized patients.

    Time frame: From the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 124 events, whichever comes first

  2. PFS in slow-early responder (SER) patients

    Will compare PFS among SER patients randomized to IO therapy and involved-site radiation therapy against arms containing standard therapy. PFS curves will be estimated separately by arm using Kaplan Meier methodology, and the test will be a 1-sided log-rank test between the (pooled) IO and standard arms, stratified according to the stratification factors at randomization and including all eligible and evaluable randomized patients.

    Time frame: From the time of randomization to the earliest time of disease relapse, progression, or death due to any cause, assessed up to 3 years after the randomization of the last patient or when reaching 71 events, whichever comes first

Secondary outcomes

  1. Overall survival (OS) in RER patients

    The non-inferiority of IO therapy to standard therapy will be tested in the randomized and eligible RER cohort using a confidence interval approach performed 12 years after the last patient not lost to follow-up has reached more than 12 years of follow-up (patients are followed up to 13 years).

    Time frame: Time from randomization to death due to any cause, assessed up to 12 years after the last enrollment

  2. OS in SER patients

    Will be compared between a standard chemotherapy approach and an IO therapy approach among the SER patients.

    Time frame: Time from randomization to death due to any cause, assessed up to 12 years after the last enrollment

  3. OS for entire patient population

    Will be based on a confidence interval approach conducted after the last patient not lost to follow-up has been followed for at least 12 years from randomization. Twelve-year OS and its corresponding 90% confidence interval will be estimated with the Kaplan-Meier method for each study arm within the entire randomized and evaluable trial population.

    Time frame: Time from randomization to death due to any cause, assessed at 12 years after the last enrollment

  4. PFS for favorable risk patients

    Will be estimated in patients with favorable features at diagnosis. PFS and a corresponding confidence interval will be estimated using the Kaplan-Meier approach. PFS will also be compared between the (pooled) IO therapy and standard therapy arms using stratified log-rank tests within each cohort.

    Time frame: Up to 12 years

  5. PFS for unfavorable risk patients

    Will be estimated in patients with unfavorable features at diagnosis. PFS and a corresponding confidence interval will be estimated using the Kaplan-Meier approach. PFS will also be compared between the (pooled) IO therapy and standard therapy arms using stratified log-rank tests within each cohort.

    Time frame: Up to 12 years

  6. PFS for entire population

    PFS and a corresponding confidence interval will be estimated using the Kaplan-Meier approach. PFS will also be compared between the (pooled) IO therapy and standard therapy arms using stratified log-rank tests within each cohort.

    Time frame: Up to 12 years

  7. Event-free survival (EFS)

    Pooling IO treatment arms and standard treatment arms, EFS and corresponding confidence intervals will be estimated with the Kaplan-Meier approach for patients assigned versus (vs.) not assigned to receive radiaton therapy (RT), and compared using the log-rank test.

    Time frame: Time from randomization to the earliest of progression, relapse, second malignancy, or death due to any cause, assessed up to 12 years from last enrollment

  8. Incidence of adverse events (AEs)

    Will use the American Society of Clinical Oncology and the Society for Immunotherapy of Cancer guidelines to capture immune-related AEs. Physician-reported treatment related AEs will be reported for all grades using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Rates of individual toxicities with grades greater or equal to 3 will be compared between the pooled IO and standard arms using exact binomial tests. The maximum grade for each toxicity will be recorded for each patient. The rates and confidence intervals for these toxicities will be provided. Comparison of AEs will also be conducted for physician-reported treatment-related AEs between RT and non-RT patients.

    Time frame: Assessed up to 12 years from last enrollment

  9. Patient reported outcomes (PRO)-CTCAE

    Targeted patient-reported AEs will be collected at each time point using the PRO-CTCAE for patients 7 years and older. For youth (7-17 years) the Pediatric PRO-CTCAE form will be used and for those 18 years and older adult the PRO-CTCAE form will be used. For information collected by each of the above forms, the scores for each attribute together with frequency, severity and/or interference will be presented descriptively using summary statistics at each assessment time. Additionally, the worst severity and/or interference over the entire course will be summarized. The changes among main time points will be calculated. The results will be provided for the whole population and compared between subpopulations by arms and by age groups. Regression models based on longitudinal measurements can be constructed by considering the following covariates besides age groups: baseline demographics, clinical risk factors, and study arms.

    Time frame: Assessed up to 12 years from last enrollment

  10. Patient-reported fatigue

    Will be measured by validated short forms from the Patient Reported Outcomes Measurement Information System initiatives. Domain scores will be converted to T-scores with an established standard deviation of 10 points with an average score normalized to 50 within the healthy adult population. The minimal clinically important difference (MCID) in these PRO measures has been accepted to be 2-3 points of the standard deviation (SD = 10) of the measure. To account for the dual primary PRO outcomes of fatigue and cognitive deficits, we will consider Bonferroni correction of p-values. Primary interests will be differences in T-scores between IO and chemotherapy arms at 1-year post completion of therapy.

    Time frame: Baseline up to 1 year from end of study treatment

  11. Patient-reported cognitive deficits

    Will be measured by validated short forms from the Neuro-QoL initiative. Domain scores will be converted to T-scores with an established standard deviation of 10 points with an average score normalized to 50 within the healthy adult population. The MCID in these PRO measures has been accepted to be 2-3 points of the standard deviation (SD = 10) of the measure. To account for the dual primary PRO outcomes of fatigue and cognitive deficits, we will consider Bonferroni correction of p-values. Primary interests will be differences in T-scores between IO and chemotherapy arms at 1-year post completion of therapy.

    Time frame: Baseline up to 1 year from end of study treatment

  12. Patient-reported health-related quality of life

    Domain scores will be converted to T-scores with an established standard deviation of 10 points with an average score normalized to 50 within the healthy adult population. The MCID in these PRO measures has been accepted to be 2-3 points of the standard deviation (SD = 10) of the measure. To account for the dual primary PRO outcomes of fatigue and cognitive deficits, we will consider Bonferroni correction of p-values. Primary interests will be differences in T-scores between IO and chemotherapy arms at 1-year post completion of therapy.

    Time frame: Baseline up to 1 year from end of study treatment

  13. Incidence of self-reported late morbidities

    Will be collected by using validated measures from the St. Jude Life Cohort. The cumulative incidence of late-morbidities (e.g., cardiovascular, pulmonary and endocrine) will be compared between the standard chemotherapy and the IO therapy and among different age groups (7-14; 15-40 and 41-60) with K-sample method. The frequencies of selected organ toxicities will be compared between two treatment arms, among the three age groups and between RT and non-RT with chi-square tests.

    Time frame: Assessed up to 12 years from last enrollment

  14. Effect of metabolic tumor burden (MTV) on PFS

    MTV will be measured at baseline using fludeoxyglucose F-18 (FDG)-PET. The Kaplan-Meier curves of PFS will be compared between the two levels with log-rank tests.

    Time frame: At baseline prior to initiation of therapy

  15. Effect of total lesion glycolysis (TLG) on PFS

    TLG will be measured at baseline using FDG-PET. The Kaplan-Meier curves of PFS will be compared between the two levels with log-rank tests.

    Time frame: At baseline prior to initiation of therapy

  16. Contribution of social determinants of health (SDOH) to PET2 response by race and ethnicity

    PET2 Response will be compared by race and ethnicity using Fisher exact tests.

    Time frame: After Cycle 2 of treatment (1 cycle = 28 days)

  17. Contribution of SDOH to PFS by race and ethnicity

    Kaplan-Meier (K-M) curves of PFS will be generated by racial/ethnic groups (e.g., non-Hispanic white \[NHW\], non-Hispanic black \[NHB\], Hispanic). The p values for the K-M curve comparison will be obtained from log-rank tests. Associations between race/ethnicity and PFS will be evaluated with univariable and multivariable Cox proportional hazard models by considering other covariates such as baseline clinical conditions, toxicities, SDOH, and treatment arm (standard vs. IO). Backward selection will be used to select those factors with p-value \< 0.2, which will be included in final multivariable models.

    Time frame: Assessed up to 12 years after last enrollment

  18. Contribution of SDOH to OS by race and ethnicity

    K-M curves of OS will be generated by racial/ethnic groups (e.g., NHW, NHB, Hispanic). The p values for the K-M curve comparison will be obtained from log-rank tests. Associations between race/ethnicity and OS will be evaluated with univariable and multivariable Cox proportional hazard models by considering other covariates such as baseline clinical conditions, toxicities, SDOH, and treatment arm (standard vs. IO). Backward selection will be used to select those factors with p-value \< 0.2, which will be included in final multivariable models.

    Time frame: Assessed up to 12 years after last enrollment

Other outcomes

  1. PFS comparison between treatment arms for each age group

    Will be compared between a standard chemotherapy approach and an IO therapy approach within different age groups (ages 5-11 years, 12-21 years, 22-39 years, 40-60 years) using log-rank tests. Cox regression models will be constructed to evaluate the treatment effects for different age groups while considering the impact of other potentially prognostic variables including baseline demographics and clinical risk factors. PFS and corresponding confidence intervals for each age group will be estimated with the Kaplan-Meier method, overall and by treatment arms. In additional models, age may be evaluated as a continuous variable with potentially non-linear effects on PFS.

    Time frame: Up to 12 years

  2. Concordance and discordance of 5-point score (PS) visual PET assessments

    The concordance and discordance of 5-PS visual PET assessment from rapid central review and local institutional review will be evaluated at each of the timepoints. Will collect and retrospectively review local vs. central review concordance rates. For discordant cases, will document the differences in treatments if only local review or only central review were performed

    Time frame: At baseline, post cycle 2, and at end of systemic therapy

  3. Association between FDG PET parameters obtained by automated measurements and PFS

    The association between FDG PET parameters obtained by automated measurements using convolutional neural networks and PFS will be evaluated in this aim. The PET parameters of interest are total MTV and TLG, tumor standardized uptake value change. PET parameters will be obtained based on artificial intelligence (AI) based measurements. The effect of these PET measurements will be evaluated by Cox regression models.

    Time frame: At baseline, post cycle 2, and at the end of therapy

  4. Agreement between AI derived FDG-PET measurement extraction and physician-based manual quantitative PET measurement

    Will compare AI derived automated quantitative FDG-PET measurement extraction and physician-based manual quantitative PET measurement with Spearman rank correlation coefficients for each extracted PET metric.

    Time frame: At baseline, post cycle 2, and at the end of therapy

  5. Incidence of patient reported adverse events and provider adverse event reporting

    Will be collected by PRO-CTCAE and Ped-PRO-CTCAE. The patient reported AEs will be compared to provider reported AEs reported descriptively.

    Time frame: Assessed up to 12 years

  6. Association between self-reported race/ethnicity and dimensional SDOH

    Will be evaluated by Chi-square tests or Fisher exact tests for sparse data. Will also calculate the area deprivation index (derived from patient-reported address and zip code to census block-group data for patients treated in the United States, and the Canadian Index of Multiple Deprivation for patients treated in Canada) and investigate its association with race/ethnicity and SDOH.

    Time frame: Assessed up to 12 years

  7. Post-relapse/post-progression OS by race/ethnicity and select SDOH measures

    The K-M curves will be presented together with p-values via log-rank tests across the different race/ethnicity groups for each treatment arm. Cox proportional hazard models to evaluate the relationship between race/ethnicity and post-relapse OS will be constructed.

    Time frame: Assessed up to 12 years

  8. Completion rate of PRO and health-related quality of life contact forms

    Will be evaluated for the first 450 eligible participants.

    Time frame: At 1 year off treatment

07

Study locations

404 of 419 sites recruiting

Showing the first 100 of 419 sites across 3 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Castellino SM, Giulino-Roth L, Harker-Murray P, Kahn JM, Forlenza C, Cho S, Hoppe B, Parsons SK, Kelly KM; COG Hodgkin Lymphoma Committee. Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30580. doi: 10.1002/pbc.30580. Epub 2023 Jul 28. PubMed 37505794 ↗

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page

Data sharing details ↗ · grants.nih.gov

09

Timeline

25 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Apr 2031, 95 months after the start.

Of 27 non-industry phase 3 interventional studies under Hodgkin Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 108. This study's planned 95 months is above that.

Counting every sponsor, half of 33 studies reached it within 75 months; a quarter within 52 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2023
First posted
Jan 9, 2023
StartActual
May 11, 2023
Primary completionEst.
Apr 28, 2031
CompletionEst.
Apr 28, 2031
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 1 site removed. 10 sites changed recruiting status (6 now recruiting, 4 now suspended)
Show 10 sites
  • Henry Ford Health Providence Southfield Hospital · Southfield, United StatesRecruiting→Suspended
  • Providence Newberg Medical Center · Newberg, United StatesSuspended→Recruiting
  • Providence Willamette Falls Medical Center · Oregon City, United StatesSuspended→Recruiting
  • Valley Medical Center · Renton, United StatesRecruiting→Suspended
  • University of Miami Miller School of Medicine-Sylvester Cancer Center · Miami, United StatesRecruiting→Suspended
  • Trinity Health Grand Rapids Hospital · Grand Rapids, United StatesSuspended→Recruiting
  • Cancer and Hematology Centers of Western Michigan - Norton Shores · Norton Shores, United StatesSuspended→Recruiting
  • Cooperman Barnabas Medical Center · Livingston, United StatesSuspended→Recruiting
  • Beacon Kalamazoo Cancer Center · Kalamazoo, United StatesSuspended→Recruiting
  • Rush-Copley Healthcare Center · Yorkville, United StatesRecruiting→Suspended
Show 5 added (5 United States)
  • Vandalia Health/CAMC Institute for Academic Medicine · Charleston, United States
  • Cancer Center at Saint Joseph's · Phoenix, United States
  • Henry Ford Saint John Hospital - Macomb Medical · Macomb, United States
  • Prisma Health Cancer Institute - Seneca · Seneca, United States
  • Minnesota Oncology - Edina · Edina, United States
Show 1 removed
  • West Virginia University Charleston Division · Charleston, United States
across 21 updates, Oct 1, 2026 – Nov 5, 2026
Site contacts
Changed at 34 sites. See the sites
Show 34 sites
  • West Virginia University Charleston Division · Charleston, United StatesContact none listed→C•••@vandaliahealth.org
  • Memorial Health University Medical Center · Savannah, United StatesContact person changed (no phone or email listed)
  • Connecticut Children's Medical Center · Hartford, United StatesContact added •••9981Contact added (no phone or email listed)
  • Providence Portland Medical Center · Portland, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  • Providence Saint Vincent Medical Center · Portland, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  • Rush-Copley Medical Center · Aurora, United StatesContact person changed (no phone or email listed)
  • Henry Ford Health Providence Southfield Hospital · Southfield, United StatesContact removed k•••@hfhs.org · •••5332Contact removed (no phone or email listed)
  • Henry Ford Macomb Hospital-Clinton Township · Clinton Township, United StatesContact added C•••@hfhs.org · •••3721Contact added (no phone or email listed)
  • Henry Ford West Bloomfield Hospital · West Bloomfield, United StatesContact added C•••@hfhs.org · •••3721Contact added (no phone or email listed)
  • Thomas Jefferson University Hospital · Philadelphia, United StatesContact person changed (no phone or email listed)
  • Nicklaus Children's Hospital · Miami, United StatesContact added •••2778Contact added (no phone or email listed)
  • Providence Newberg Medical Center · Newberg, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  • Providence Willamette Falls Medical Center · Oregon City, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  • Corewell Health Farmington Hills Hospital · Farmington Hills, United StatesContact added •••7695Contact added (no phone or email listed)
  • CTCA at Western Regional Medical Center · Goodyear, United StatesContact person changed (no phone or email listed)
  • Alliance for Childhood Diseases/Cure 4 the Kids Foundation · Las Vegas, United StatesContact person changed (no phone or email listed)
  • Valley Medical Center · Renton, United StatesContact removed r•••@valleymed.org · •••3440Contact removed (no phone or email listed)
  • Children's Hospital Medical Center of Akron · Akron, United StatesContact person changed (no phone or email listed)
  • Scott and White Memorial Hospital · Temple, United StatesContact added •••5407Contact added (no phone or email listed)
  • University of Miami Miller School of Medicine-Sylvester Cancer Center · Miami, United StatesContact removed •••2647Contact removed (no phone or email listed)
  • Trinity Health Grand Rapids Hospital · Grand Rapids, United StatesContact added c•••@crcwm.org · •••1230Contact added (no phone or email listed)
  • Cancer and Hematology Centers of Western Michigan - Norton Shores · Norton Shores, United StatesContact added c•••@crcwm.org · •••1230Contact added (no phone or email listed)
  • Cooperman Barnabas Medical Center · Livingston, United StatesContact added •••5200Contact added (no phone or email listed)
  • Wayne State University/Karmanos Cancer Institute · Detroit, United StatesContact added c•••@karmanos.org · •••6266Contact added (no phone or email listed)
  • Weisberg Cancer Treatment Center · Farmington Hills, United StatesContact added c•••@karmanos.org · •••9790Contact added (no phone or email listed)
  • Cancer Center at Saint Joseph's · Phoenix, United StatesContact person changed (no phone or email listed)
  • Mercy Cancer Center - Carmichael · Carmichael, United StatesContact person changed (no phone or email listed)
  • Mercy San Juan Medical Center · Carmichael, United StatesContact person changed (no phone or email listed)
  • Mercy Cancer Center - Elk Grove · Elk Grove, United StatesContact person changed (no phone or email listed)
  • Mercy Cancer Center - Rocklin · Rocklin, United StatesContact person changed (no phone or email listed)
  • …and 4 more sites
across 21 updates, Sep 29, 2026 – Nov 12, 2026
Show all 25 updates
  1. Nov 12, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Thomas Jefferson University Hospital · Philadelphia, United StatesContact person changed (no phone or email listed)
  2. Nov 5, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Wayne State University/Karmanos Cancer Institute · Detroit, United StatesSuspended→Recruiting
    • Weisberg Cancer Treatment Center · Farmington Hills, United StatesSuspended→Recruiting
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Wayne State University/Karmanos Cancer Institute · Detroit, United StatesContact added c•••@karmanos.org · •••6266Contact added (no phone or email listed)
    • Weisberg Cancer Treatment Center · Farmington Hills, United StatesContact added c•••@karmanos.org · •••9790Contact added (no phone or email listed)
  3. Nov 3, 2026
    Rush-Copley Healthcare Center is now Suspended
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Rush-Copley Healthcare Center · Yorkville, United StatesContact removed C•••@rushcopley.com · •••6212Contact removed (no phone or email listed)
  4. Nov 2, 2026
    4 sites changed recruiting status (2 now recruiting, 2 now suspended)
    Show 4 sites
    • Henry Ford Macomb Hospital-Clinton Township · Clinton Township, United StatesSuspended→Recruiting
    • Wayne State University/Karmanos Cancer Institute · Detroit, United StatesRecruiting→Suspended
    • Weisberg Cancer Treatment Center · Farmington Hills, United StatesRecruiting→Suspended
    • Beacon Kalamazoo Cancer Center · Kalamazoo, United StatesSuspended→Recruiting
    Site contacts Changed at 11 sites. See the sites
    Show 11 sites
    • Cancer Center at Saint Joseph's · Phoenix, United StatesContact person changed (no phone or email listed)
    • Mercy Cancer Center - Carmichael · Carmichael, United StatesContact person changed (no phone or email listed)
    • Mercy San Juan Medical Center · Carmichael, United StatesContact person changed (no phone or email listed)
    • Mercy Cancer Center - Elk Grove · Elk Grove, United StatesContact person changed (no phone or email listed)
    • Mercy Cancer Center - Rocklin · Rocklin, United StatesContact person changed (no phone or email listed)
    • Mercy Cancer Center - Sacramento · Sacramento, United StatesContact person changed (no phone or email listed)
    • Woodland Memorial Hospital · Woodland, United StatesContact person changed (no phone or email listed)
    • Henry Ford Macomb Hospital-Clinton Township · Clinton Township, United StatesContact added C•••@hfhs.org · •••3721Contact added (no phone or email listed)
    • Wayne State University/Karmanos Cancer Institute · Detroit, United StatesContact removed c•••@karmanos.org · •••6266Contact removed (no phone or email listed)
    • Weisberg Cancer Treatment Center · Farmington Hills, United StatesContact removed c•••@karmanos.org · •••9790Contact removed (no phone or email listed)
    • Beacon Kalamazoo Cancer Center · Kalamazoo, United StatesContact added •••7370Contact added (no phone or email listed)
  5. Oct 29, 2026
    Corewell Health Farmington Hills Hospital is now Recruiting
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Wayne State University/Karmanos Cancer Institute · Detroit, United StatesContact person changed (no phone or email listed)
    • Weisberg Cancer Treatment Center · Farmington Hills, United StatesContact person changed (no phone or email listed)
    • Corewell Health Farmington Hills Hospital · Farmington Hills, United StatesContact added •••7695Contact added (no phone or email listed)
  6. Oct 28, 2026
    Cooperman Barnabas Medical Center is now Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Cooperman Barnabas Medical Center · Livingston, United StatesContact added •••5200Contact added (no phone or email listed)
  7. Oct 27, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Children's Hospital Medical Center of Akron · Akron, United StatesContact person changed (no phone or email listed)
  8. Oct 26, 2026
    1 site added
    Show site
    • Minnesota Oncology - Edina · Edina, United States
  9. Oct 23, 2026
    1 site added
    Show site
    • Prisma Health Cancer Institute - Seneca · Seneca, United States
  10. Oct 22, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Trinity Health Grand Rapids Hospital · Grand Rapids, United StatesSuspended→Recruiting
    • Cancer and Hematology Centers of Western Michigan - Norton Shores · Norton Shores, United StatesSuspended→Recruiting
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Trinity Health Grand Rapids Hospital · Grand Rapids, United StatesContact added c•••@crcwm.org · •••1230Contact added (no phone or email listed)
    • Cancer and Hematology Centers of Western Michigan - Norton Shores · Norton Shores, United StatesContact added c•••@crcwm.org · •••1230Contact added (no phone or email listed)
  11. Oct 21, 2026
    2 sites changed recruiting status (1 now suspended, 1 now recruiting)
    Show 2 sites
    • University of Miami Miller School of Medicine-Sylvester Cancer Center · Miami, United StatesRecruiting→Suspended
    • Scott and White Memorial Hospital · Temple, United StatesSuspended→Recruiting
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • University of Miami Miller School of Medicine-Sylvester Cancer Center · Miami, United StatesContact removed •••2647Contact removed (no phone or email listed)
    • Scott and White Memorial Hospital · Temple, United StatesContact added •••5407Contact added (no phone or email listed)
  12. Oct 20, 2026
    Children's Hospital Medical Center of Akron is now Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Children's Hospital Medical Center of Akron · Akron, United StatesContact added •••3193Contact added (no phone or email listed)
  13. Oct 19, 2026
    2 sites changed recruiting status (2 now suspended)
    Show 2 sites
    • Children's Hospital Medical Center of Akron · Akron, United StatesRecruiting→Suspended
    • Scott and White Memorial Hospital · Temple, United StatesRecruiting→Suspended
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Children's Hospital Medical Center of Akron · Akron, United StatesContact removed •••3193Contact removed (no phone or email listed)
    • Scott and White Memorial Hospital · Temple, United StatesContact removed •••5407Contact removed (no phone or email listed)
  14. Oct 16, 2026
    Valley Medical Center is now Suspended
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • CTCA at Western Regional Medical Center · Goodyear, United StatesContact person changed (no phone or email listed)
    • Alliance for Childhood Diseases/Cure 4 the Kids Foundation · Las Vegas, United StatesContact person changed (no phone or email listed)
    • Valley Medical Center · Renton, United StatesContact removed r•••@valleymed.org · •••3440Contact removed (no phone or email listed)
  15. Oct 15, 2026
    Corewell Health Farmington Hills Hospital is now Suspended
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Corewell Health Farmington Hills Hospital · Farmington Hills, United StatesContact removed •••7695Contact removed (no phone or email listed)
  16. Oct 14, 2026
    5 sites changed recruiting status (5 now recruiting)
    Show 5 sites
    • Nicklaus Children's Hospital · Miami, United StatesSuspended→Recruiting
    • Providence Newberg Medical Center · Newberg, United StatesSuspended→Recruiting
    • Providence Willamette Falls Medical Center · Oregon City, United StatesSuspended→Recruiting
    • Providence Portland Medical Center · Portland, United StatesSuspended→Recruiting
    • Providence Saint Vincent Medical Center · Portland, United StatesSuspended→Recruiting
    Site contacts Changed at 5 sites. See the sites
    Show 5 sites
    • Nicklaus Children's Hospital · Miami, United StatesContact added •••2778Contact added (no phone or email listed)
    • Providence Newberg Medical Center · Newberg, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
    • Providence Willamette Falls Medical Center · Oregon City, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
    • Providence Portland Medical Center · Portland, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
    • Providence Saint Vincent Medical Center · Portland, United StatesContact added C•••@providence.org · •••2614Contact added (no phone or email listed)
  17. Oct 13, 2026
    2 sites changed recruiting status (1 now suspended, 1 now recruiting)
    Show 2 sites
    • Nicklaus Children's Hospital · Miami, United StatesRecruiting→Suspended
    • Henry Ford West Bloomfield Hospital · West Bloomfield, United StatesSuspended→Recruiting
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Nicklaus Children's Hospital · Miami, United StatesContact removed •••2778Contact removed (no phone or email listed)
    • Henry Ford West Bloomfield Hospital · West Bloomfield, United StatesContact added C•••@hfhs.org · •••3721Contact added (no phone or email listed)
  18. Oct 9, 2026
    2 sites changed recruiting status (2 now suspended)
    Show 2 sites
    • Henry Ford Macomb Hospital-Clinton Township · Clinton Township, United StatesRecruiting→Suspended
    • Henry Ford West Bloomfield Hospital · West Bloomfield, United StatesRecruiting→Suspended
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Henry Ford Macomb Hospital-Clinton Township · Clinton Township, United StatesContact removed C•••@hfhs.org · •••3721Contact removed (no phone or email listed)
    • Henry Ford West Bloomfield Hospital · West Bloomfield, United StatesContact removed C•••@hfhs.org · •••3721Contact removed (no phone or email listed)
    • Thomas Jefferson University Hospital · Philadelphia, United StatesContact person changed (no phone or email listed)
  19. Oct 8, 2026
    Henry Ford Health Providence Southfield Hospital is now Suspended
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Rush-Copley Medical Center · Aurora, United StatesContact person changed (no phone or email listed)
    • Henry Ford Health Providence Southfield Hospital · Southfield, United StatesContact removed k•••@hfhs.org · •••5332Contact removed (no phone or email listed)
  20. Oct 7, 2026
    Connecticut Children's Medical Center is now Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Connecticut Children's Medical Center · Hartford, United StatesContact added •••9981Contact added (no phone or email listed)
  21. Oct 6, 2026
    1 site added. 3 sites changed recruiting status (3 now suspended)
    Show 3 sites
    • Connecticut Children's Medical Center · Hartford, United StatesRecruiting→Suspended
    • Providence Portland Medical Center · Portland, United StatesRecruiting→Suspended
    • Providence Saint Vincent Medical Center · Portland, United StatesRecruiting→Suspended
    Show site
    • Henry Ford Saint John Hospital - Macomb Medical · Macomb, United States
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Connecticut Children's Medical Center · Hartford, United StatesContact removed •••9981Contact removed (no phone or email listed)
    • Providence Portland Medical Center · Portland, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
    • Providence Saint Vincent Medical Center · Portland, United StatesContact removed C•••@providence.org · •••2614Contact removed (no phone or email listed)
  22. Oct 5, 2026
    1 site added
    Show site
    • Cancer Center at Saint Joseph's · Phoenix, United States
  23. Oct 2, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Memorial Health University Medical Center · Savannah, United StatesContact person changed (no phone or email listed)
  24. Oct 1, 2026
    1 site added, 1 site removed
    Show site
    • Vandalia Health/CAMC Institute for Academic Medicine · Charleston, United States
    Show 1 removed
    • West Virginia University Charleston Division · Charleston, United States
  25. Sep 29, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • West Virginia University Charleston Division · Charleston, United StatesContact none listed→C•••@vandaliahealth.org

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05675410
Responsible party
Sponsor
First posted
Jan 9, 2023
Start date
May 11, 2023
Primary completion
Apr 28, 2031 (estimated)
Completion
Apr 28, 2031 (estimated)
Last update
Nov 12, 2026

Study contacts

Kara M Kelly
principal investigator · Roswell Park Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brentuximab Vedotin · Cyclophosphamide · Etoposide · Etoposide phosphate · Nivolumab · Prednisolone · Prednisone · Procarbazine · Vincristine

Start the discussion